A randomized controlled trial of visible-light therapy for the prevention of oral mucositis

Sharon, Elad; Luboshitz-Shon, Noa; Cohen, Tehila; Wainchwaig, Elad; Shapira, Michael Y.; Resnick, Igor B.; Radiano, Ruth; Lubart, Rachel; Or, Reuven

doi:10.1016/j.oraloncology.2010.11.013

Cited by 23 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant variations were noted in PTPs (Table 2). An RCT using visible light supports this guideline as the peak of the emission spectrum used in this study was in the range of 625-660 nm (Table 2: entire spectrum used-top row; peak of the emission spectrum-bottom row) [27]. Extra-oral PBM for the management of OM was reported to have a beneficial effect in the prevention of OM in HSCT patients (Table 3).…”

Section: Prevention Of Oral Mucositis In Hematopoietic Stem Cell Transplantationsupporting

confidence: 59%

“…Guideline The panel recommends the use of intra-oral PBM therapy using low-level laser therapy for the prevention of OM in adult patients receiving HSCT conditioned with high-dose CT, with or without total body irradiation using one of the selected protocols in Table 1 (LoE I); following the specific PTPs of the selected protocol is recommended for optimal therapy. Intra-oral PBM was reported to be beneficial for the prevention of OM and related pain in HSCT patients in numerous RCTs (Table 2) [8,15,[22][23][24][25][26][27]44]. The overall trend noted from the available evidence is that intra-oral PBM therapy at wavelengths of 630 to 660 nm (red) is beneficial for preventing OM and related pain in HSCT patients.…”

Section: Prevention Of Oral Mucositis In Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines

Zadik

Arany²,

Fregnani

et al. 2019

Support Care Cancer

Self Cite

282

176

View full text Add to dashboard Cite

Purpose To systematically review the literature and update the evidence-based clinical practice guidelines for the use of photobiomodulation (PBM), such as laser and other light therapies, for the prevention and/or treatment of oral mucositis (OM). Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using PubMed and Web of Science. We followed the MASCC methods for systematic review and guidelines development. The rigorously evaluated evidence for each intervention, in each cancer treatment setting, was assigned a level-of-evidence (LoE). Based on the LoE, one of the following guidelines was determined: Recommendation, Suggestion, or No Guideline Possible. Results Recommendations are made for the prevention of OM and related pain with PBM therapy in cancer patients treated with one of the following modalities: hematopoietic stem cell transplantation, head and neck (H&N) radiotherapy (without chemotherapy), and H&N radiotherapy with chemotherapy. For each of these modalities, we recommend 1-2 clinically effective protocols; the clinician should adhere to all parameters of the protocol selected. Due to inadequate evidence, currently, No Guideline Possible for treatment of established OM or for management of chemotherapy-related OM. The reported clinical settings were extremely variable, limiting data integration. Conclusions The evidence supports the use of specific settings of PBM therapy for the prevention of OM in specific patient populations. Under these circumstances, PBM is recommended for the prevention of OM. The guidelines are subject to continuous update based on new published data.

show abstract

Section: Prevention Of Oral Mucositis In Hematopoietic Stem Cell Transplantationsupporting

confidence: 59%

Section: Prevention Of Oral Mucositis In Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines

Zadik

Arany²,

Fregnani

et al. 2019

Support Care Cancer

Self Cite

282

176

View full text Add to dashboard Cite

show abstract

“…Visible light irradiation has been investigated in numerous in vitro and in vivo trials as well as in small clinical trials. While the data is generally of low methodological quality, the results have been mostly positive and the treatment effectiveness appears to be comparable to laser or LED photobiomodulation [52, 53].…”

Section: Can Broadband Light Also Be Used For Photobiomodulation?mentioning

confidence: 99%

Photobiomodulation: lasers vs. light emitting diodes?

Heiskanen

Hamblin

2018

Photochem Photobiol Sci

243

View full text Add to dashboard Cite

Photobiomodulation (PBM) is a treatment method based on research findings showing that irradiation with certain wavelengths of red or near-infrared light has been shown to produce a range of physiological effects in cells, tissues, animals and humans. Scientific research into PBM was initially started in the late 1960s by utilizing the newly invented (1960) lasers, and the therapy rapidly became known as "low-level laser therapy". It was mainly used for wound healing and reduction of pain and inflammation. Despite other light sources being available during the first 40 years of PBM research, lasers remained by far the most commonly employed device, and in fact, some authors insisted that lasers were essential to the therapeutic benefit. Collimated, coherent, highly monochromatic beams with the possibility of high power densities were considered preferable. However in recent years, non-coherent light sources such as light-emitting diodes (LEDs) and broad-band lamps have become common. Advantages of LEDs include no laser safety considerations, ease of home use, ability to irradiate a large area of tissue at once, possibility of wearable devices, and much lower cost per mW. LED photobiomodulation is here to stay.

show abstract

“…These epithelial barriers often recover quickly posttransplant but protective secretions such as IgA or lysozyme can be chronically subnormal in those with chronic GVHD [1]. Mucosal integrity early posttransplant can be improved by peritransplant administration of palifermin [76] or by phototherapy [77,78]. It is not known whether these strategies lead to decreased infections or GVHD.…”

Section: Innate Immunitymentioning

confidence: 99%